South Korean AI‑driven protein discovery company Galux signed a research collaboration with Boehringer Ingelheim to evaluate AI‑enabled design of purpose‑specific protein molecules. The initial phase will validate AI‑designed proteins across selected cases, following Galux’s de novo antibody design milestone claims earlier this year. Executives framed the deal as moving AI beyond prediction toward engineered molecules with tailored translational properties, setting up potential broader research programs between the biotech and big pharma partner.